Skip to content
10-Q

Quarterly Report

Pear Therapeutics, Inc.

0001835567-22-000036

← back to feed
Filed
May 16, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 12, 2022 138.1M sh
Shares Diluted Q1 2022 · Mar 31, 2022 137.85M sh
Shares Diluted Q1 2022 · Mar 31, 2021 108.66M sh
Capex Q1 2022 · Mar 31, 2022 $501K
Capex Q1 2022 · Mar 31, 2021 $789K
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$36.71M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$20.96M
Long Term Debt Q1 2022 · Mar 31, 2022 $0
Short Term Debt Q1 2022 · Mar 31, 2022 $27.17M
Short Term Debt Q1 2022 · Dec 31, 2021 $26.99M
Short Term Investments Q1 2022 · Mar 31, 2022 $47.97M
Short Term Investments Q1 2022 · Dec 31, 2021 $5M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $89.43M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $169.57M
Stockholders Equity Q1 2022 · Mar 31, 2022 $69.51M
Stockholders Equity Q1 2022 · Dec 31, 2021 $90.43M
Stockholders Equity restated Q1 2022 · Mar 31, 2021 $85.56M
Stockholders Equity restated Q1 2022 · Dec 31, 2020 $87.12M
Current Liabilities Q1 2022 · Mar 31, 2022 $46.38M
Current Liabilities Q1 2022 · Dec 31, 2021 $47.17M
Total Liabilities Q1 2022 · Mar 31, 2022 $102.58M
Total Liabilities Q1 2022 · Dec 31, 2021 $106.73M
Current Assets Q1 2022 · Mar 31, 2022 $150.05M
Current Assets Q1 2022 · Dec 31, 2021 $185.24M
Total Assets Q1 2022 · Mar 31, 2022 $172.09M
Total Assets Q1 2022 · Dec 31, 2021 $197.16M
Eps Diluted Q1 2022 · Mar 31, 2022 −$0.17
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.22
Eps Basic Q1 2022 · Mar 31, 2022 −$0.17
Eps Basic Q1 2022 · Mar 31, 2021 −$0.22
Sga Expense Q1 2022 · Mar 31, 2022 $22.75M
Sga Expense Q1 2022 · Mar 31, 2021 $13.3M
Rd Expense Q1 2022 · Mar 31, 2022 $13.26M
Rd Expense Q1 2022 · Mar 31, 2021 $7.49M
Net Income Q1 2022 · Mar 31, 2022 −$23.86M
Net Income restated Q1 2022 · Mar 31, 2021 −$24.39M
Operating Income Q1 2022 · Mar 31, 2022 −$34.74M
Operating Income restated Q1 2022 · Mar 31, 2021 −$21.15M
Cost Of Revenue Q1 2022 · Mar 31, 2022 $1.48M
Cost Of Revenue Q1 2022 · Mar 31, 2021 $738K
Revenue Q1 2022 · Mar 31, 2022 $2.75M
Revenue Q1 2022 · Mar 31, 2021 $376K